Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

PHASE4TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
DepressionRelapsing-remitting Multiple Sclerosis
Interventions
DRUG

Venlafaxine

Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg

DRUG

Fluoxetine

Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg

DRUG

Citalopram

Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg

DRUG

Fingolimod

Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.

Trial Locations (25)

12621

Novartis Investigative Site, Berlin

14471

Novartis Investigative Site, Potsdam

24161

Novartis Investigative Site, Altenholz-Stift

26122

Novartis Investigative Site, Oldenburg

27574

Novartis Investigative Site, Bremerhaven

28832

Novartis Investigative Site, Achim

31582

Novartis Investigative Site, Nienburg

33602

Novartis Investigative Site, Bielefeld

33647

Novartis Investigative Site, Bielefeld

34613

Novartis Investigative Site, Schwalmstadt-Treysa

35510

Novartis Investigative Site, Butzbach

41515

Novartis Investigative Site, Grevenbroich

44787

Novartis Investigative Site, Bochum

46045

Novartis Investigative Site, Oberhausen

52499

Novartis Investigative Site, Baesweiler

53604

Novartis Investigative Site, Bad Honnef

63739

Novartis Investigative Site, Aschaffenburg

66663

Novartis Investigative Site, Merzig

72076

Novartis Investigative Site, Tübingen

76889

Novartis Investigative Site, Klingenmünster

79576

Novartis Investigative Site, Weil am Rhein

89518

Novartis Investigative Site, Heidenheim

04275

Novartis Investigative Site, Leipzig

07646

Novartis Investigative Site, Stadtroda

08060

Novartis Investigative Site, Zwickau

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY